HLS vs. GUD, WEED, CPH, ACB, SUGR, OGI, FIRE, EPI, ICC, and RIV
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Knight Therapeutics (GUD), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), SugarBud Craft Growers (SUGR), Organigram (OGI), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), and RIV Capital (RIV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs. Its Competitors
HLS Therapeutics (TSE:HLS) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
HLS Therapeutics currently has a consensus target price of C$5.00, suggesting a potential downside of 10.55%. Knight Therapeutics has a consensus target price of C$7.15, suggesting a potential upside of 12.78%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than HLS Therapeutics.
0.4% of HLS Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Knight Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, HLS Therapeutics had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for Knight Therapeutics. HLS Therapeutics' average media sentiment score of 0.29 beat Knight Therapeutics' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.
Knight Therapeutics has a net margin of -8.81% compared to HLS Therapeutics' net margin of -38.70%. Knight Therapeutics' return on equity of -4.04% beat HLS Therapeutics' return on equity.
HLS Therapeutics has a beta of 0.650839, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.219245, meaning that its share price is 78% less volatile than the S&P 500.
HLS Therapeutics has higher earnings, but lower revenue than Knight Therapeutics.
Summary
Knight Therapeutics beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 9/12/2025 by MarketBeat.com Staff
Free HLS Stock Alerts